April 16
Through a different lens: How Kath Giles and OncoRes Are Reinventing Breast Cancer Surgery
Read more
Brandon BioCatalyst is the largest life science investment fund in Australia and New Zealand. We are a unique collaboration between major Australian superannuation funds, CSL, the Australian and New Zealand governments, Australian state governments and more than 50 leading medical research institutes and research hospitals.
Learn more about who we areA clinical stage company developing treatment for hot flashes in cancer survivors undergoing endocrine therapy
View ProjectDeveloping disease-modifying mitochondrial therapeutics for neurodegenerative disorders
View ProjectDeveloping the next generation of CAR-T cell therapies to treat solid cancers
View ProjectCombining non-opioid analgesics and biopolymers to deliver weeks of localised pain management
View ProjectUnlocking the potential of N-myristoyltransferase (NMT) to develop precision medicines for a range of diseases including cancer and viral infections
View ProjectGlyscend is developing novel non-absorbable polymers that are orally-delivered for the treatment of Type 2 Diabetes.
View ProjectQIMR Berghofer is one of Australia’s most successful medical research institutes. The Institute was established 70 years ago by the Queensland Government and has a rich history of scientific discoveries and translational medical research.
ViewBetter lives through advanced medical technologies.
ViewBrandon BioCatalyst is innovation in action: We provide a path for taking medical science from conception into the real world.
Our Venture capital model is unique. We don’t simply provide investment, we partner with entrepreneurs to create businesses, run companies and everything necessary to ensure our investments succeed.
Learn moreThrough a different lens: How Kath Giles and OncoRes Are Reinventing Breast Cancer Surgery
Read moreENA Respiratory: The Difference Between Chance and Discovery? Knowing What to Do Next.
Read moreMeet Proxima Bio: Australia’s next-generation biotech startup aiming to clean up cancer-causing proteins.
Read moreCombination of First-in-Class Systemic TLR2/6 Agonist and Anti-PD-1 Monoclonal Antibody to be Studied in Patients with Advanced Solid Tumours
Read more